Mycoplasma Testing Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2032
Description
Persistence Market Research has recently released a comprehensive report on the worldwide market for mycoplasma testing. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global mycoplasma testing market from 2025 to 2032.
Key Insights:
Mycoplasma testing is critical for ensuring the quality and safety of cell cultures used in biopharmaceutical production, research, and clinical applications. These tests detect mycoplasma contamination, which can compromise experimental results, reduce product yield, and affect therapeutic safety. The market serves biopharmaceutical companies, contract research organizations (CROs), and cell banks, providing a range of testing technologies including PCR, ELISA, direct assays, and microbial culture methods. Increasing demand for high-quality biologics, strict regulatory standards, and rising adoption of advanced detection technologies are key drivers of market expansion.
Market Growth Drivers:
The global mycoplasma testing market is propelled by multiple factors, including stringent regulatory requirements for cell-based products and biologics, increasing adoption of advanced molecular testing methods, and the rising need to ensure contamination-free cell cultures in research and manufacturing. Growing investments in biotechnology research, expansion of biopharmaceutical production facilities, and increasing prevalence of cell therapy development contribute to robust market growth. Moreover, the shift toward automated and high-throughput testing solutions enhances testing efficiency and reduces human error, further driving market adoption.
Market Restraints:
Despite strong growth potential, the mycoplasma testing market faces challenges including high costs of advanced testing kits, complexity of regulatory compliance, and technical limitations in detecting low levels of contamination. In emerging economies, limited access to sophisticated testing infrastructure and trained personnel can impede market penetration. Addressing these barriers requires collaboration among industry stakeholders, investment in training, and innovation in cost-effective testing technologies.
Market Opportunities:
The mycoplasma testing market offers opportunities through technological advancements, such as rapid PCR-based detection methods, integration of automated testing platforms, and development of multiparametric kits for simultaneous pathogen detection. Expansion in cell and gene therapy, stem cell research, and regenerative medicine presents new avenues for market growth. Strategic partnerships between testing solution providers and biopharmaceutical companies, as well as increased awareness of contamination risks, are key to capitalizing on these opportunities.
Key Questions Answered in the Report:
Leading companies in the global mycoplasma testing market, including Thermo Fisher Scientific, Inc., Lonza Group AG, and Merck KGaA, focus on innovation, product differentiation, and strategic collaborations to maintain market leadership. These companies invest in R&D to develop highly sensitive, rapid, and user-friendly testing solutions, including PCR kits, ELISA assays, and automated platforms. Collaborations with biopharmaceutical manufacturers, CROs, and research institutions facilitate market penetration and adoption. Emphasis on regulatory compliance, quality assurance, and validation studies enhances trust and reliability in testing solutions.
Key Companies Profiled:
By Technology:
Key Insights:
- Mycoplasma Testing Market Size (2025E): USD 1.89 Billion
- Projected Market Value (2032F): USD 4.52 Billion
- Global Market Growth Rate (CAGR 2025 to 2032): 11.5%
Mycoplasma testing is critical for ensuring the quality and safety of cell cultures used in biopharmaceutical production, research, and clinical applications. These tests detect mycoplasma contamination, which can compromise experimental results, reduce product yield, and affect therapeutic safety. The market serves biopharmaceutical companies, contract research organizations (CROs), and cell banks, providing a range of testing technologies including PCR, ELISA, direct assays, and microbial culture methods. Increasing demand for high-quality biologics, strict regulatory standards, and rising adoption of advanced detection technologies are key drivers of market expansion.
Market Growth Drivers:
The global mycoplasma testing market is propelled by multiple factors, including stringent regulatory requirements for cell-based products and biologics, increasing adoption of advanced molecular testing methods, and the rising need to ensure contamination-free cell cultures in research and manufacturing. Growing investments in biotechnology research, expansion of biopharmaceutical production facilities, and increasing prevalence of cell therapy development contribute to robust market growth. Moreover, the shift toward automated and high-throughput testing solutions enhances testing efficiency and reduces human error, further driving market adoption.
Market Restraints:
Despite strong growth potential, the mycoplasma testing market faces challenges including high costs of advanced testing kits, complexity of regulatory compliance, and technical limitations in detecting low levels of contamination. In emerging economies, limited access to sophisticated testing infrastructure and trained personnel can impede market penetration. Addressing these barriers requires collaboration among industry stakeholders, investment in training, and innovation in cost-effective testing technologies.
Market Opportunities:
The mycoplasma testing market offers opportunities through technological advancements, such as rapid PCR-based detection methods, integration of automated testing platforms, and development of multiparametric kits for simultaneous pathogen detection. Expansion in cell and gene therapy, stem cell research, and regenerative medicine presents new avenues for market growth. Strategic partnerships between testing solution providers and biopharmaceutical companies, as well as increased awareness of contamination risks, are key to capitalizing on these opportunities.
Key Questions Answered in the Report:
- What are the primary factors driving the growth of the global mycoplasma testing market?
- Which technologies and end-users are driving market adoption?
- How are innovations in assay development reshaping the competitive landscape?
- Who are the leading players in the mycoplasma testing market, and what strategies are they using to sustain growth?
- What are the emerging trends and future growth prospects in global mycoplasma testing?
Leading companies in the global mycoplasma testing market, including Thermo Fisher Scientific, Inc., Lonza Group AG, and Merck KGaA, focus on innovation, product differentiation, and strategic collaborations to maintain market leadership. These companies invest in R&D to develop highly sensitive, rapid, and user-friendly testing solutions, including PCR kits, ELISA assays, and automated platforms. Collaborations with biopharmaceutical manufacturers, CROs, and research institutions facilitate market penetration and adoption. Emphasis on regulatory compliance, quality assurance, and validation studies enhances trust and reliability in testing solutions.
Key Companies Profiled:
- Thermo Fisher Scientific, Inc.
- Lonza Group AG
- Merck KGaA
- Charles River Laboratories International, Inc.
- PromoCell GmbH
- American Type Culture Collection (ATCC)
- Asahi Kasei Medical Co., Ltd
- Sartorius AG
- InvivoGen
- Eurofins Scientific
By Technology:
- PCR
- ELISA
- Direct Assay
- Microbial Culture
- Biopharmaceutical
- CROs
- Cell Banks
- Assays
- Kits
- Reagents
- North America
- Europe
- Asia Pacific
- South Asia and Oceania
- Latin America
- Middle East and Africa
Table of Contents
192 Pages
- 1. Executive Summary
- 1.1. Mycoplasma Testing Market Snapshot, 2025 and 2032
- 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
- 2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.4. COVID-19 Impact Analysis
- 2.5. Forecast Factors - Relevance and Impact
- 3. Value Added Insights
- 3.1. Regulatory Landscape
- 3.2. Pipeline Analysis
- 3.3. Product Adoption Analysis
- 3.4. Value Chain Analysis
- 3.5. Key Promotional Strategies by Manufacturers
- 3.6. PESTLE Analysis
- 3.7. Porter’s Five Force Analysis
- 4. Mycoplasma Testing Market Outlook:
- 4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
- 4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
- 4.2.2. Market Size (US$ Bn) Analysis and Forecast, 2025-2032
- 4.3. Global Mycoplasma Testing Market Outlook: Technology
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2024
- 4.3.3. Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 4.3.3.1. PCR
- 4.3.3.2. ELISA
- 4.3.3.3. Direct Assay
- 4.3.3.4. Microbial Culture
- 4.3.4. Market Attractiveness Analysis: Technology
- 4.4. Global Mycoplasma Testing Market Outlook: End-user
- 4.4.1. Introduction / Key Findings
- 4.4.2. Historical Market Size (US$ Bn) Analysis, End-user, 2019-2024
- 4.4.3. Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
- 4.4.3.1. Biopharmaceutical
- 4.4.3.2. CROs
- 4.4.3.3. Cell Banks
- 4.4.4. Market Attractiveness Analysis: End-user
- 4.5. Global Mycoplasma Testing Market Outlook: Product & Service
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Bn) Analysis, By Product & Service, 2019-2024
- 4.5.3. Market Size (US$ Bn) Analysis and Forecast, By Product & Service, 2025-2032
- 4.5.3.1. Assays
- 4.5.3.2. Kits
- 4.5.3.3. Reagents
- 4.5.4. Market Attractiveness Analysis: Product & Service
- 5. Global Mycoplasma Testing Market Outlook: Region
- 5.1. Key Highlights
- 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
- 5.3. Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. South Asia and Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
- 5.4. Market Attractiveness Analysis: Region
- 6. North America Mycoplasma Testing Market Outlook:
- 6.1. Key Highlights
- 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 6.2.1. By Technology
- 6.2.2. By End-user
- 6.2.3. By Product & Service
- 7. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 7.1. U.S.
- 7.2. Canada
- 7.3. Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 7.3.1. PCR
- 7.3.2. ELISA
- 7.3.3. Direct Assay
- 7.3.4. Microbial Culture
- 7.4. Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
- 7.4.1. Biopharmaceutical
- 7.4.2. CROs
- 7.4.3. Cell Banks
- 7.5. Market Size (US$ Bn) Analysis and Forecast, By Product & Service, 2025-2032
- 7.5.1. Assays
- 7.5.2. Kits
- 7.5.3. Reagents
- 7.6. Market Attractiveness Analysis
- 8. Europe Mycoplasma Testing Market Outlook:
- 8.1. Key Highlights
- 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 8.2.1. By Country
- 8.2.2. By Technology
- 8.2.3. By End-user
- 8.2.4. By Product & Service
- 8.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 8.3.1. Germany
- 8.3.2. France
- 8.3.3. U.K.
- 8.3.4. Italy
- 8.3.5. Spain
- 8.3.6. Russia
- 8.3.7. Turkey
- 8.3.8. Rest of Europe
- 8.4. Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 8.4.1. PCR
- 8.4.2. ELISA
- 8.4.3. Direct Assay
- 8.4.4. Microbial Culture
- 8.5. Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
- 8.5.1. Biopharmaceutical
- 8.5.2. CROs
- 8.5.3. Cell Banks
- 8.6. Market Size (US$ Bn) Analysis and Forecast, By Product & Service, 2025-2032
- 8.6.1. Assays
- 8.6.2. Kits
- 8.6.3. Reagents
- 8.7. Market Attractiveness Analysis
- 9. East Asia Mycoplasma Testing Market Outlook:
- 9.1. Key Highlights
- 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 9.2.1. By Country
- 9.2.2. By Technology
- 9.2.3. By End-user
- 9.2.4. By Product & Service
- 9.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. South Korea
- 9.4. Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 9.4.1. PCR
- 9.4.2. ELISA
- 9.4.3. Direct Assay
- 9.4.4. Microbial Culture
- 9.5. Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
- 9.5.1. Biopharmaceutical
- 9.5.2. CROs
- 9.5.3. Cell Banks
- 9.6. Market Size (US$ Bn) Analysis and Forecast, By Product & Service, 2025-2032
- 9.6.1. Assays
- 9.6.2. Kits
- 9.6.3. Reagents
- 9.7. Market Attractiveness Analysis
- 10. South Asia & Oceania Mycoplasma Testing Market Outlook:
- 10.1. Key Highlights
- 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 10.2.1. By Country
- 10.2.2. By Technology
- 10.2.3. By End-user
- 10.2.4. By Product & Service
- 10.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 10.3.1. India
- 10.3.2. Southeast Asia
- 10.3.3. ANZ
- 10.3.4. Rest of South Asia & Oceania
- 10.4. Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 10.4.1. PCR
- 10.4.2. ELISA
- 10.4.3. Direct Assay
- 10.4.4. Microbial Culture
- 10.5. Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
- 10.5.1. Biopharmaceutical
- 10.5.2. CROs
- 10.5.3. Cell Banks
- 10.6. Market Size (US$ Bn) Analysis and Forecast, By Product & Service, 2025-2032
- 10.6.1. Assays
- 10.6.2. Kits
- 10.6.3. Reagents
- 10.7. Market Attractiveness Analysis
- 11. Latin America Mycoplasma Testing Market Outlook:
- 11.1. Key Highlights
- 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 11.2.1. By Country
- 11.2.2. By Technology
- 11.2.3. By End-user
- 11.2.4. By Product & Service
- 11.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 11.3.1. Brazil
- 11.3.2. Mexico
- 11.3.3. Rest of Latin America
- 11.4. Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 11.4.1. PCR
- 11.4.2. ELISA
- 11.4.3. Direct Assay
- 11.4.4. Microbial Culture
- 11.5. Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
- 11.5.1. Biopharmaceutical
- 11.5.2. CROs
- 11.5.3. Cell Banks
- 11.6. Market Size (US$ Bn) Analysis and Forecast, By Product & Service, 2025-2032
- 11.6.1. Assays
- 11.6.2. Kits
- 11.6.3. Reagents
- 11.7. Market Attractiveness Analysis
- 12. Middle East & Africa Mycoplasma Testing Market Outlook:
- 12.1. Key Highlights
- 12.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 12.2.1. By Country
- 12.2.2. By Technology
- 12.2.3. By End-user
- 12.2.4. By Product & Service
- 12.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 12.3.1. GCC Countries
- 12.3.2. Egypt
- 12.3.3. South Africa
- 12.3.4. Northern Africa
- 12.3.5. Rest of Middle East & Africa
- 12.4. Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 12.4.1. PCR
- 12.4.2. ELISA
- 12.4.3. Direct Assay
- 12.4.4. Microbial Culture
- 12.5. Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
- 12.5.1. Biopharmaceutical
- 12.5.2. CROs
- 12.5.3. Cell Banks
- 12.6. Market Size (US$ Bn) Analysis and Forecast, By Product & Service, 2025-2032
- 12.6.1. Assays
- 12.6.2. Kits
- 12.6.3. Reagents
- 12.7. Market Attractiveness Analysis
- 13. Competition Landscape
- 13.1. Market Share Analysis, 2025
- 13.2. Market Structure
- 13.2.1. Competition Intensity Mapping By Market
- 13.2.2. Competition Dashboard
- 13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 13.3.1. Thermo Fisher Scientific, Inc.
- 13.3.1.1. Overview
- 13.3.1.2. Segments and Products
- 13.3.1.3. Key Financials
- 13.3.1.4. Market Developments
- 13.3.1.5. Market Strategy
- 13.3.2. Lonza Group AG
- 13.3.3. Merck KGaA
- 13.3.4. Charles River Laboratories International, Inc.
- 13.3.5. PromoCell GmbH
- 13.3.6. American Technology Culture Collection
- 13.3.7. Asahi Kasei Medical Co., Ltd.
- 13.3.8. Sartorius AG
- 13.3.9. InvivoGen
- 13.3.10. Eurofins Scientific
- 13.3.11. (ATCC) American Technology Culture Collection
- 14. Appendix
- 14.1. Research Methodology
- 14.2. Research Assumptions
- 14.3. Acronyms and Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
